This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Stocks in Motion

Get Jim Cramer's picks for 2006.

NeoPharm (NEOL) was the best-performing drug stock Tuesday after an independent panel recommended the continuation of a phase III trial using its cintredekin besudotox to treat brain cancer. The decision was significant news in a trial where 160 of about 300 enrolled patients are expected to succumb to their illness by the end of the second quarter of 2006. NeoPham's drug is a recombinant protein composed of a tumor-targeting molecule and a cytotoxic agent and is delivered via catheters placed in areas with microscopic tumor spread or that are at risk of tumor spread. NeoPharm shares were up 49% to $11.81.

Shares of Guidant (GDT) fell after the company issued disappointing earnings guidance and disclosed the receipt of a warning letter from the Food and Drug Administration. The pacemaker company, which is the subject of two competing takeover offers, said late Friday that fourth-quarter earnings would trail analysts' estimates due to the impact of several high-profile pacemaker malfunctions on consumer tastes. It also said it received a warning letter from the FDA regarding a manufacturing plant in Wisconsin. The letter, which focused on quality control practices, should not result in a material impact on the company's financial results, Guidant said. Recently, the shares were down 3.3% to $64.79.

The developments didn't sway Boston Scientific (BSX) from its resolve to buy Guidant under the $25 billion takeover offer it proffered last month. A Boston Scientific spokesman told Reuters: "We continue to move forward with our due diligence with the goal of reaching a definitive agreement with Guidant." Boston Scientific's shares were down 2.5% to $25.20 while shares of Johnson & Johnson (JNJ), another suitor, lost 0.7% to $60.67.

Pfizer (PFE) said it invested $50 million in Perlegen Sciences, a former Affymetrix (AFFX) unit that does genomics research. Pfizer bought a 12% stake in the company through the purchase of preferred stock and agreed to buy up to $25 million more if Perlegen goes public in 2006. The two companies have been research partners since December 2002, when Pfizer used Perlegen's DNA sample preparation and other products to discover genes associated with common diseases and identify genetic markers.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs